MRKR Annual EBITDA
-$14.58 M
+$5.21 M+26.32%
31 December 2023
Summary:
As of January 20, 2025, MRKR annual earnings before interest, taxes, depreciation & amortization is -$14.58 million, with the most recent change of +$5.21 million (+26.32%) on December 31, 2023. During the last 3 years, it has risen by +$12.76 million (+46.67%). MRKR annual EBITDA is now -3738.22% below its all-time high of -$379.90 thousand, reached on December 31, 2001.MRKR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRKR Quarterly EBITDA
-$2.40 M
-$91.80 K-3.98%
30 September 2024
Summary:
As of January 20, 2025, MRKR quarterly earnings before interest, taxes, depreciation & amortization is -$2.40 million, with the most recent change of -$91.80 thousand (-3.98%) on September 30, 2024. Over the past year, it has dropped by -$91.80 thousand (-3.98%). MRKR quarterly EBITDA is now -125.28% below its all-time high of $9.49 million, reached on December 31, 2009.MRKR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRKR TTM EBITDA
-$10.19 M
+$800.10 K+7.28%
30 September 2024
Summary:
As of January 20, 2025, MRKR TTM earnings before interest, taxes, depreciation & amortization is -$10.19 million, with the most recent change of +$800.10 thousand (+7.28%) on September 30, 2024. Over the past year, it has increased by +$800.10 thousand (+7.28%). MRKR TTM EBITDA is now -222.18% below its all-time high of $8.34 million, reached on December 31, 2009.MRKR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRKR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +26.3% | -4.0% | +7.3% |
| 3 y3 years | +46.7% | -4.0% | +7.3% |
| 5 y5 years | +90.2% | +58.3% | +55.6% |
MRKR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +59.9% | -4.0% | +73.2% | at high | +72.6% |
| 5 y | 5-year | at high | +59.9% | -4.0% | +76.3% | at high | +72.6% |
| alltime | all time | -3738.2% | +90.2% | -125.3% | +98.2% | -222.2% | +93.3% |
Marker Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.40 M(+4.0%) | -$10.19 M(-7.3%) |
| June 2024 | - | -$2.31 M(-9.5%) | -$10.99 M(-14.2%) |
| Mar 2024 | - | -$2.55 M(-13.2%) | -$12.82 M(-12.1%) |
| Dec 2023 | -$14.58 M(-26.3%) | -$2.94 M(-8.2%) | -$14.58 M(-0.7%) |
| Sept 2023 | - | -$3.20 M(-22.6%) | -$14.68 M(-15.2%) |
| June 2023 | - | -$4.13 M(-4.1%) | -$17.31 M(-6.2%) |
| Mar 2023 | - | -$4.31 M(+41.8%) | -$18.44 M(-20.1%) |
| Dec 2022 | -$19.79 M(-45.5%) | -$3.04 M(-47.8%) | -$23.09 M(-20.4%) |
| Sept 2022 | - | -$5.83 M(+10.6%) | -$29.00 M(-10.5%) |
| June 2022 | - | -$5.27 M(-41.2%) | -$32.39 M(-13.0%) |
| Mar 2022 | - | -$8.96 M(+0.2%) | -$37.25 M(+2.6%) |
| Dec 2021 | -$36.32 M(+32.8%) | -$8.94 M(-3.0%) | -$36.32 M(+2.5%) |
| Sept 2021 | - | -$9.22 M(-9.0%) | -$35.41 M(+6.7%) |
| June 2021 | - | -$10.13 M(+26.2%) | -$33.18 M(+15.2%) |
| Mar 2021 | - | -$8.03 M(-0.2%) | -$28.81 M(+5.4%) |
| Dec 2020 | -$27.34 M(+24.1%) | -$8.04 M(+15.1%) | -$27.34 M(+12.2%) |
| Sept 2020 | - | -$6.99 M(+21.5%) | -$24.37 M(+6.1%) |
| June 2020 | - | -$5.75 M(-12.3%) | -$22.96 M(-0.2%) |
| Mar 2020 | - | -$6.56 M(+29.5%) | -$23.01 M(+4.4%) |
| Dec 2019 | -$22.03 M(-85.1%) | -$5.07 M(-9.1%) | -$22.03 M(-85.6%) |
| Sept 2019 | - | -$5.58 M(-3.8%) | -$152.83 M(+0.8%) |
| June 2019 | - | -$5.80 M(+3.9%) | -$151.68 M(+0.9%) |
| Mar 2019 | - | -$5.58 M(-95.9%) | -$150.35 M(+1.6%) |
| Dec 2018 | -$147.97 M(+1209.8%) | -$135.87 M(+2968.2%) | -$147.97 M(+901.5%) |
| Sept 2018 | - | -$4.43 M(-0.9%) | -$14.77 M(+4.4%) |
| June 2018 | - | -$4.47 M(+39.7%) | -$14.15 M(+17.2%) |
| Mar 2018 | - | -$3.20 M(+19.3%) | -$12.08 M(+6.9%) |
| Dec 2017 | -$11.30 M(+36.7%) | -$2.68 M(-29.6%) | -$11.30 M(+10.7%) |
| Sept 2017 | - | -$3.81 M(+59.1%) | -$10.21 M(+11.9%) |
| June 2017 | - | -$2.39 M(-1.0%) | -$9.12 M(+2.2%) |
| Mar 2017 | - | -$2.42 M(+51.9%) | -$8.92 M(+8.0%) |
| Dec 2016 | -$8.26 M(-75.7%) | -$1.59 M(-41.5%) | -$8.26 M(-77.6%) |
| Sept 2016 | - | -$2.72 M(+24.0%) | -$36.82 M(+2.7%) |
| June 2016 | - | -$2.19 M(+25.1%) | -$35.84 M(+3.0%) |
| Mar 2016 | - | -$1.75 M(-94.2%) | -$34.78 M(+2.1%) |
| Dec 2015 | -$34.06 M(+12.4%) | -$30.15 M(+1634.8%) | -$34.06 M(+633.8%) |
| Sept 2015 | - | -$1.74 M(+52.7%) | -$4.64 M(+4.2%) |
| June 2015 | - | -$1.14 M(+10.7%) | -$4.46 M(+74.4%) |
| Mar 2015 | - | -$1.03 M(+39.6%) | -$2.56 M(-91.7%) |
| Dec 2014 | -$30.31 M(+702.6%) | -$736.50 K(-52.6%) | -$30.72 M(-6.3%) |
| Sept 2014 | - | -$1.55 M(-303.7%) | -$32.77 M(+4.0%) |
| June 2014 | - | $762.10 K(-102.6%) | -$31.52 M(-4.1%) |
| Mar 2014 | - | -$29.19 M(+944.9%) | -$32.86 M(+770.2%) |
| Dec 2013 | -$3.78 M(-30.4%) | -$2.79 M(+841.8%) | -$3.78 M(+39.7%) |
| Sept 2013 | - | -$296.60 K(-48.8%) | -$2.70 M(-8.7%) |
| June 2013 | - | -$579.60 K(+444.2%) | -$2.96 M(-41.2%) |
| Mar 2013 | - | -$106.50 K(-93.8%) | -$5.03 M(-7.3%) |
| Dec 2012 | -$5.43 M | -$1.72 M(+210.8%) | -$5.42 M(+67.7%) |
| Sept 2012 | - | -$553.30 K(-79.1%) | -$3.24 M(-5.5%) |
| June 2012 | - | -$2.65 M(+428.1%) | -$3.42 M(+217.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$501.80 K(-206.8%) | -$1.08 M(-18.3%) |
| Dec 2011 | -$1.35 M(-41.1%) | $469.80 K(-163.4%) | -$1.32 M(+48.6%) |
| Sept 2011 | - | -$740.50 K(+141.8%) | -$888.70 K(+26.3%) |
| June 2011 | - | -$306.30 K(-58.8%) | -$703.60 K(-55.1%) |
| Mar 2011 | - | -$743.60 K(-182.5%) | -$1.57 M(-31.6%) |
| Dec 2010 | -$2.29 M(-45.3%) | $901.70 K(-262.4%) | -$2.29 M(-136.4%) |
| Sept 2010 | - | -$555.40 K(-52.5%) | $6.30 M(-1.3%) |
| June 2010 | - | -$1.17 M(-20.4%) | $6.39 M(-10.8%) |
| Mar 2010 | - | -$1.47 M(-115.5%) | $7.16 M(-14.2%) |
| Dec 2009 | -$4.19 M(+180.6%) | $9.49 M(-2116.3%) | $8.34 M(-432.1%) |
| Sept 2009 | - | -$470.90 K(+19.2%) | -$2.51 M(-19.5%) |
| June 2009 | - | -$395.10 K(+38.9%) | -$3.12 M(-15.1%) |
| Mar 2009 | - | -$284.50 K(-79.1%) | -$3.68 M(-4.6%) |
| Dec 2008 | -$1.49 M(-40.4%) | -$1.36 M(+26.1%) | -$3.85 M(+14.3%) |
| Sept 2008 | - | -$1.08 M(+13.8%) | -$3.37 M(+20.8%) |
| June 2008 | - | -$949.20 K(+106.2%) | -$2.79 M(+3.9%) |
| Mar 2008 | - | -$460.40 K(-47.6%) | -$2.68 M(+7.1%) |
| Dec 2007 | -$2.51 M(+184.1%) | -$878.80 K(+75.8%) | -$2.51 M(+31.9%) |
| Sept 2007 | - | -$499.80 K(-40.8%) | -$1.90 M(+9.8%) |
| June 2007 | - | -$843.90 K(+198.4%) | -$1.73 M(+65.5%) |
| Mar 2007 | - | -$282.80 K(+3.4%) | -$1.05 M(+18.6%) |
| Dec 2006 | -$881.90 K(+10.1%) | -$273.50 K(-17.1%) | -$881.70 K(+81.6%) |
| Sept 2006 | - | -$329.90 K(+107.0%) | -$485.40 K(+3.9%) |
| June 2006 | - | -$159.40 K(+34.1%) | -$467.20 K(-38.4%) |
| Mar 2006 | - | -$118.90 K(-196.8%) | -$758.60 K(-5.0%) |
| Dec 2005 | -$801.20 K(-68.6%) | $122.80 K(-139.4%) | -$798.40 K(-58.3%) |
| Sept 2005 | - | -$311.70 K(-30.9%) | -$1.91 M(-4.0%) |
| June 2005 | - | -$450.80 K(+184.1%) | -$1.99 M(-3.0%) |
| Mar 2005 | - | -$158.70 K(-84.0%) | -$2.05 M(-19.6%) |
| Dec 2004 | -$2.55 M(-55.5%) | -$991.60 K(+153.9%) | -$2.55 M(-38.9%) |
| Sept 2004 | - | -$390.60 K(-23.7%) | -$4.18 M(-12.4%) |
| June 2004 | - | -$511.60 K(-22.4%) | -$4.77 M(-13.7%) |
| Mar 2004 | - | -$659.60 K(-74.8%) | -$5.53 M(-3.6%) |
| Dec 2003 | -$5.74 M(+155.7%) | -$2.62 M(+166.6%) | -$5.74 M(+35.0%) |
| Sept 2003 | - | -$982.70 K(-22.6%) | -$4.25 M(+11.7%) |
| June 2003 | - | -$1.27 M(+47.0%) | -$3.80 M(+7.9%) |
| Mar 2003 | - | -$864.00 K(-23.7%) | -$3.53 M(+22.2%) |
| Dec 2002 | -$2.24 M(+490.6%) | -$1.13 M(+111.2%) | -$2.88 M(+61.1%) |
| Sept 2002 | - | -$536.40 K(-45.9%) | -$1.79 M(+36.6%) |
| June 2002 | - | -$992.30 K(+346.0%) | -$1.31 M(+297.1%) |
| Mar 2002 | - | -$222.50 K(+461.9%) | -$330.20 K(-11.9%) |
| Dec 2001 | -$379.90 K(-16.9%) | -$39.60 K(-30.2%) | -$374.60 K(-210.1%) |
| Sept 2001 | - | -$56.70 K(+397.4%) | $340.30 K(-658.8%) |
| June 2001 | - | -$11.40 K(-95.7%) | -$60.90 K(-46.0%) |
| Mar 2001 | - | -$266.90 K(-139.5%) | -$112.70 K(-19.2%) |
| Dec 2000 | -$457.20 K(-56.3%) | $675.30 K(-247.5%) | -$139.50 K(-82.9%) |
| Sept 2000 | - | -$457.90 K(+624.5%) | -$814.80 K(+128.3%) |
| June 2000 | - | -$63.20 K(-78.5%) | -$356.90 K(+21.5%) |
| Mar 2000 | - | -$293.70 K | -$293.70 K |
| Dec 1999 | -$1.05 M | - | - |
FAQ
- What is Marker Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Marker Therapeutics?
- What is Marker Therapeutics annual EBITDA year-on-year change?
- What is Marker Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Marker Therapeutics?
- What is Marker Therapeutics quarterly EBITDA year-on-year change?
- What is Marker Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Marker Therapeutics?
- What is Marker Therapeutics TTM EBITDA year-on-year change?
What is Marker Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of MRKR is -$14.58 M
What is the all time high annual EBITDA for Marker Therapeutics?
Marker Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$379.90 K
What is Marker Therapeutics annual EBITDA year-on-year change?
Over the past year, MRKR annual earnings before interest, taxes, depreciation & amortization has changed by +$5.21 M (+26.32%)
What is Marker Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of MRKR is -$2.40 M
What is the all time high quarterly EBITDA for Marker Therapeutics?
Marker Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $9.49 M
What is Marker Therapeutics quarterly EBITDA year-on-year change?
Over the past year, MRKR quarterly earnings before interest, taxes, depreciation & amortization has changed by -$91.80 K (-3.98%)
What is Marker Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of MRKR is -$10.19 M
What is the all time high TTM EBITDA for Marker Therapeutics?
Marker Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $8.34 M
What is Marker Therapeutics TTM EBITDA year-on-year change?
Over the past year, MRKR TTM earnings before interest, taxes, depreciation & amortization has changed by +$800.10 K (+7.28%)